The Apollo Gamma Camera System is intended to produce images depicting the anatomical distributions of single photon emitting radioisotopes within the human body for interpretation by medical personnel.

Device Description

The Apollo Gamma Camera System offers all the features of the Forte™ Gamma Camera System (K033254) while adding the following new features: Caudal/Cephalic Imaging, a second LEHR collimator with improved sensitivity, new CHR collimator, larger Field of View (FOV) with square cornered detectors, < 3-inch brain reach, 3/4' detector crystal (in lieu of 5/8"), Automatic Body Contouring (ABC) with BodyGuard™, MegaBody Mode Imaging, 9-axis ring gantry, extra large patient bore (38" diameter), cart-based semi-automatic exchanger, optional chamfered pallet for low edge attenuation, DICOM MPPS, additional Data Management features (Audit Trail & Patient Privacy), support for new detector, and port server applications from Solaris to LINUX.

Caudal/Cephalic Imaging will allow rotational "tilt" motion of at least one of the detectors about an axis of the detector (parallel to the face of the ring) of at least ±15 degrees. MegaBody mode imaging provides independent variable height positioning of the detectors which includes caudal/cephalic angulations. The detector FOV reach for brain imaging will be less than 3 inches while the detector FOV will be larger (15.5" x 21" instead of 15" x 20") due to the use of the square cornered detectors. In all these cases, the basic functionality of the detector will remain the same (as the detector in the Forte™), while adding detector flexibility to provide a better view of the heart and brain and improve image quality.

The use of ¾" crystal in lieu of the 5/8" crystal for applications that require higher energy isotopes is now a common trend in the medical device industry. The ¾" crystal has higher system sensitivity (per NEMA NU-1, Section 3.8) than the 5/8" crystal. Another improvement to the system sensitivity is the use of a second type of LEHR collimator in the Apollo System. Higher system sensitivity will improve image quality and may reduce acquisition time and/or applied radiopharmaceutical dosage to the patient. A new collimator will also be used, CHR (aka Rembrandt™ Collimators) which is long-bore collimation that eliminates dead-space in the 90° corner and preserving resolution at depth. This collimator is a variation of the VXGP collimator used in the Forte™ System.

The ABC mode with BodyGuard™ is an addition to the current manual mapping feature available in the Forte System. It is a refinement of the non-circular SPECT and learn-mode TB currently used in Forte™. Also, the BodyGuard™ is the sensing mechanism providing the same functionality as the Collision Avoidance feature in Forte™.

The 9-axis gantry frame provides additional gantry motions designed to improve image quality. Also, the larger bore diameter provides openness for even the largest patients. The cart-based collimator exchanger uses a semi-automatic approach to simultaneously change both collimators. The chamfered pallet option is the same material and basic design as the standard pallet used for the Apollo System. It may be used in lieu of the standard pallet for certain studies that require low edge attenuation.

DICOM MPPS completes the DICOM suite and is a computerized notification stating the type of study being done and when it has been completed. Audit Trail and Patient Privacy are Data Management programs to comply with HIPAA requirements. The remote desktop feature is used in the Forte™ system by remote service personnel. To enhance this feature, remote monitoring will be added to the Apollo System.

The Apollo System is designed to provide extended imaging functionality relative to a ring style gantry. It is designed for single or dual detector nuclear imaging accommodating a broad range of emission computed tomography (ECT) studies. The device includes the gantry frame, display panel, two detectors, a collimator storage unit, an acquisition computer unit (with an optional customer desk), a patient imaging table (includes pallet catcher), and a hand controller. The patient imaging table (pallet) is mechanized for patient loading access and for movement during imaging studies. The table may be removed by the operator for imaging of patients in wheelchairs, beds, or gurneys. The pallet includes removable arm, leg/knee, shoulder and headrest supports for patient positioning during studies that require support.

The Apollo is designed to allow acquisition of a broad range of imaging studies using single or dual detectors. When using either a single detector or dual detectors placed in a relative 90-degree or relative 180-degree positions (as study appropriate). Apollo can be used to perform static, dynamic, gated, total body, circular-orbit and noncircular orbit SPECT studies, coincidence studies, gated SPECT (circular and noncircular) studies, computer-programmed protocol strings, and reference scans (dual detectors only). SPECT and total body acquisitions are routinely acquired with two detectors. There are some planar procedures such as bone statics and lung scan that also use two detectors. There are many additional nuclear medicine procedures that only use one detector at a time. These single detector procedures are typically renal. gastric emptying, hepatobiliary, flow studies, GI bleed, thyroid, and delayed static views.

AI/ML Overview

This document is a 510(k) Summary for the Apollo Gamma Camera System, comparing it to a predicate device, the Forte™ Gamma Camera System. The focus of the submission is on establishing substantial equivalence rather than performing a clinical study with detailed acceptance criteria and performance metrics for a new diagnostic device.

Therefore, the requested information regarding acceptance criteria, study details, and performance evaluations cannot be fully extracted as such a study is not part of this 510(k) submission.

Here's a breakdown of why the specific questions cannot be answered based on the provided text, and what can be inferred:

1. A table of acceptance criteria and the reported device performance

Cannot be provided directly. The document does not specify quantitative acceptance criteria or detailed performance metrics from a formal clinical study. It describes features and improvements over a predicate device.
Inferred Acceptance Criteria: Substantial equivalence to the predicate device in terms of intended use, indications for use, technological comparison, and overall system performance.
Reported Device Performance: Instead of specific performance metrics, the document highlights improvements and new features that contribute to better image quality, flexibility, and potentially reduced acquisition time/radiopharmaceutical dosage.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

Not applicable / Not provided. This 510(k) summary does not describe a clinical study with a test set of patient data being evaluated for device performance. It focuses on engineering and design comparisons with a predicate device.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

Not applicable / Not provided. Since there's no clinical study involving interpretation of images by experts to establish ground truth, this information is not present.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Not applicable / Not provided. See explanation for #3.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. The device is a gamma camera system, a hardware imaging device, not an AI-powered diagnostic software. Therefore, an MRMC study comparing human readers with and without AI assistance is not relevant or described.

6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done

Not applicable. This is a hardware system, not a standalone algorithm.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

Not applicable / Not provided. As no specific clinical performance study for image interpretation is described, ground truth establishment is not discussed. The "ground truth" for this submission is implicitly the performance and safety established for the predicate device.

8. The sample size for the training set

Not applicable / Not provided. This document describes a new hardware system (gamma camera) and its features, not a machine learning or AI model that requires a training set.

9. How the ground truth for the training set was established

Not applicable / Not provided. See explanation for #8.

Summary of what the document does provide in relation to "acceptance criteria" and "proof":

Acceptance Criteria (Implicit): Substantial equivalence to the predicate device (Forte™ Gamma Camera System) in intended use, indications for use, technological characteristics, and overall system performance.
Proof (Argument for Substantial Equivalence):
- Identical Intended Use and Indications For Use.
- Technological Comparison: Stating that Apollo and Forte™ are "technologically equivalent" with the same main mechanical and electrical components.
- New Features: Detailing enhancements in Apollo (e.g., Caudal/Cephalic Imaging, larger FOV, 3/4" detector crystal, ABC with BodyGuard™, 9-axis gantry, DICOM MPPS) that are presented as improvements that maintain or enhance safety and effectiveness, rather than fundamentally altering the device's mechanism or intended use. These improvements aim to "improve image quality," "reduce acquisition time and/or applied radiopharmaceutical dosage."
- NEMA NU-1 Standard: Mentioning that the 3/4" crystal has higher system sensitivity "per NEMA NU-1, Section 3.8," indicating adherence to recognized performance standards for imaging devices.

In conclusion, this 510(k) summary is a regulatory filing for substantial equivalence based on design and feature comparison, not a clinical trial report with explicit acceptance criteria and corresponding performance data from a patient study.

Summary

{0}------------------------------------------------

AUG 2 3 2006

510(k) SUMMARY SAFETY AND EFFECTIVENES

A.	Submitted By:ADAC Laboratories540 Alder Dr.Milpitas, CA 95035	Contact: Annie WrightTel: (408) 468-3779Fax: (408) 965-2026
B.	Device Trade Name:Common Name:Classification Name:Device Class:Product Code:	Apollo Gamma Camera SystemGamma Camera SystemsEmission Computed Tomography System21 CFR 892.1200, Class II90 KPS
C.	Date prepared:	July 21, 2006
D.	Predicate Device:	Forte™ Gamma Camera System (K033254)

E. Intended Use:
The Apollo Gamma Camera System is intended to produce images depicting the anatomical distributions of single photon emitting radioisotopes within the human body for interpretation by medical personnel.

Device Description: F.

{1}------------------------------------------------

crystal. Another improvement to the system sensitivity is the use of a second type of LEHR collimator in the Apollo System. Higher system sensitivity will improve image quality and may reduce acquisition time and/or applied radiopharmaceutical dosage to the patient. A new collimator will also be used, CHR (aka Rembrandt™ Collimators) which is long-bore collimation that eliminates dead-space in the 90° corner and preserving resolution at depth. This collimator is a variation of the VXGP collimator used in the Forte™ System.

{2}------------------------------------------------

also use two detectors. There are many additional nuclear medicine procedures that only use one detector at a time. These single detector procedures are typically renal. gastric emptying, hepatobiliary, flow studies, GI bleed, thyroid, and delayed static views.

G. Technological Comparison:

The modified Apollo Gamma Camera System and Forte™ Gamma Camera System have identical intended use and indications for use. The Apollo and the Forte™ are technologically equivalent. They have the same main mechanical and electrical components. All the features (except for the attenuation correction and Outer Room (related to detector 2 rotation)) provided on the Forte™ are provided on the Apollo. New features include: Caudal/Cephalic Imaging, second LEHR collimator with improved sensitivity, new CHR collimator, larger Field of View (FOV) with square cornered detectors, < 3-inch brain reach, 34" detector crystal (in lieu of 5/8"), Automatic Body Contouring (ABC) with BodyGuard™, MegaBody Mode Imaging, 9-axis ring gantry, extra large patient bore (38" diameter), cart-based semi-automatic exchanger, optional chamfered pallet for low edge attenuation. DICOM MPPS, additional Data Management features (Audit Trail & Patient Privacy), support for new detector, and port server applications from Solaris to LINUX.

H. Conclusion

The Apollo Gamma Camera System is substantially equivalent to the predicate device Forte™ based upon identical indications for use, technological comparison and overall system performance.

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows a circular logo with the Department of Health & Human Services (USA) written around the perimeter. In the center of the logo is a stylized symbol that resembles three abstract human figures or forms. The logo is in black and white.

AUG 2 8 2006

Food and Drug Administration 9200 Corporate Blvd. Rockville MD 20850

ADAC Laboratories, Inc. % Mr. Morten Simon Christensen Staff Engineer & FDA Office Coordinator Underwriters Laboratories, Inc. 455 East Trimble Road SAN JOSE CA 95131

Re: K062298

Trade/Device Name: Apollo Gamma Camera System Regulation Number: 21 CFR 892.1200 Regulation Name: Emission computed tomography system Regulatory Class: II Product Code: KPS Dated: August 4, 2006 Received: August 8, 2006

Dear Mr. Christensen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate comments of prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Nosmelic Act (Act) that do not require approval of a premarket approval application (PMA). Your oost. therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devines good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affective your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Image /page/3/Picture/10 description: The image is a circular logo or emblem. The text "1906-2006" is at the top of the circle. The letters "FDA" are in the center of the circle in a bold, stylized font. Below the letters, the word "Centennial" is written in a cursive font. Three stars are below the word "Centennial".

Protecting and Promoting Public Health

{4}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxx	(Gastroenterology/Renal/Urology	240-276-0115
21 CFR 884.xxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 894.xxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150

or at its Internet address http://www.fda.gov/cdrl/industry/support/index.html.

Sincerely yours,

Nancy C. Brogdon

Nancy C. B rogdon Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

INDICATIONS FOR USE STATEMENT

510 (k) NUMBER (IF KNOWN):

510 (k) NUMBER (IF KNOWN): K062278

DEVICE NAME:

Apollo Gamma Camera System

SPONSOR NAME:

ADAC Laboratories

INDICATIONS FOR USE:

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED.)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use	X (Per 21 CFR 801.109)
	OR
Over-The-Counter-Use	(Optional Format 1-2-96)

(Division Sign-Off)

Division of Reproductive, Abdominal,

and Radiological Devices

510(k) Number	K062298
---------------	---------

Regulation Number and Section

§ 892.1200 Emission computed tomography system.

(a)
Identification. An emission computed tomography system is a device intended to detect the location and distribution of gamma ray- and positron-emitting radionuclides in the body and produce cross-sectional images through computer reconstruction of the data. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.(b)
Classification. Class II.